Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 02 Nov 2022

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

in Cancer Immunity and Immunotherapy

Gretchen Bergado-Báez
Narjara Gonzalez Suarez
Lisset Chao García
Dayana Pérez-Martínez
Diana Rosa Hernández-Fernández
Talia Fundora-Barrios
Antonio Rodríguez-Álvarez
Geidy Diana Díaz-Ordaz
Moshit Lindzen
Yosef Yarden

Frontiers in Oncology

doi 10.3389/fonc.2022.951267

2,919 views
1 citation

Original Research

Published on 02 Nov 2022

A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy

in Cancer Immunity and Immunotherapy

Yu-Chong Yu
Tian-Ming Shi
Sheng-Lan Gu
Yu-Hong Li
Xiao-Ming Yang
Qiong Fan
Yu-Dong Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.1053800

3,293 views
4 citations

Original Research

Published on 31 Oct 2022

Immune marker expression of irradiated mesothelioma cell lines

in Cancer Immunity and Immunotherapy

Faith Chang
Synat Keam
Tracy Seymour Hoang
Jenette Creaney
Suki Gill
Anna K. Nowak
Martin Ebert
Alistair M. Cook

Frontiers in Oncology

doi 10.3389/fonc.2022.1020493

2,488 views
3 citations

Original Research

Published on 31 Oct 2022

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

in Cancer Immunity and Immunotherapy

Hannah Schindler
Fabienne Lusky
Lea Daniello
Mariam Elshiaty
Lena Gaissmaier
Karolina Benesova
Margarida Souto-Carneiro
Arlou Kristina Angeles
Florian Janke
Florian Eichhorn

Frontiers in Oncology

doi 10.3389/fonc.2022.1010660

4,135 views
12 citations

Original Research

Published on 25 Oct 2022

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

in Cancer Immunity and Immunotherapy

Zhaozhen Wu
Sujie Zhang
Lingling Li
Ziwei Huang
Di Huang
Yi Hu

Frontiers in Oncology

doi 10.3389/fonc.2022.887383

7,630 views
18 citations

Original Research

Published on 25 Oct 2022

Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy

in Cancer Immunity and Immunotherapy

Wenxia Li
Hangjie Fu
Liuyuan Fang
Hui Chai
Tianwen Gao
Zhenzhen Chen
Shenxian Qian

Frontiers in Oncology

doi 10.3389/fonc.2022.1025067

5,352 views
27 citations

Review

Published on 25 Oct 2022

Tumor response assessment on imaging following immunotherapy

in Cancer Immunity and Immunotherapy

Antonia M. Berz
Clarisse Dromain
Naïk Vietti-Violi
Sarah Boughdad
Rafael Duran

Frontiers in Oncology

doi 10.3389/fonc.2022.982983

14,716 views
27 citations

Original Research

Published on 25 Oct 2022

Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume

in Cancer Immunity and Immunotherapy

Younes Belkouchi
Laetitia Nebot-Bral
Littisha Lawrance
Michele Kind
Clémence David
Samy Ammari
Paul-Henry Cournède
Hugues Talbot
Perrine Vuagnat
Cristina Smolenschi

Frontiers in Oncology

doi 10.3389/fonc.2022.982790

4,158 views
6 citations

Original Research

Published on 24 Oct 2022

Early monocyte response following local ablation in hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Melanie A. Kimm
Sophia Kästle
Matthias M. R. Stechele
Elif Öcal
Lisa Richter
Muzaffer R. Ümütlü
Regina Schinner
Osman Öcal
Lukas Salvermoser
Marianna Alunni-Fabbroni

Frontiers in Oncology

doi 10.3389/fonc.2022.959987

2,362 views
1 citation

Original Research

Published on 24 Oct 2022

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis

in Cancer Immunity and Immunotherapy

Linnea A. Swanson
Ihab Kassab
Irene Tsung
Bryan J. Schneider
Robert J. Fontana

Frontiers in Oncology

doi 10.3389/fonc.2022.984940

4,837 views
16 citations

Review

Published on 21 Oct 2022

TCR mimic compounds for pHLA targeting with high potency modalities in oncology

in Cancer Immunity and Immunotherapy

Hans-Peter Gerber
Leonard G. Presta

Frontiers in Oncology

doi 10.3389/fonc.2022.1027548

10,094 views
7 citations

Original Research

Published on 21 Oct 2022

Increased expression of the RNA-binding protein Musashi-2 is associated with immune infiltration and predicts better outcomes in ccRCC patients

in Cancer Immunity and Immunotherapy

Hui Li
Xiaole Meng
Xuting You
Wenting Zhou
Wanxin Ouyang
Xin Pu
Runan Zhao
Huamei Tang

Frontiers in Oncology

doi 10.3389/fonc.2022.949705

3,542 views
6 citations

Original Research

Published on 20 Oct 2022

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Tiantian Liu
Jianni Qi
Hao Wu
Le Wang
Lihui Zhu
Chengyong Qin
Jiao Zhang
Qiang Zhu

Frontiers in Oncology

doi 10.3389/fonc.2022.993503

1,979 views
4 citations

Original Research

Published on 20 Oct 2022

SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer

in Cancer Immunity and Immunotherapy

Ying-Ying Zhao
Qian-Ming Xiang
Jia-Li Chen
Li Zhang
Wei-Long Zheng
Di Ke
Rong-Shu Shi
Kong-Wu Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.990247

2,709 views
3 citations

Editorial

Published on 18 Oct 2022

Editorial: Gastrointestinal cancer immune response and immune related adverse effects

in Cancer Immunity and Immunotherapy

Ti Wen
Yanhong Deng
Bo Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.1034890

1,018 views

Perspective

Published on 18 Oct 2022

The impact of antigenic molecular mimicry on anti-cancer T-cell immune response

in Cancer Immunity and Immunotherapy

Maria Tagliamonte
Luigi Buonaguro

Frontiers in Oncology

doi 10.3389/fonc.2022.1009247

2,502 views
6 citations